

Miriam Longo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5487082/publications.pdf>

Version: 2024-02-01

42
papers

1,138
citations

471509

17
h-index

414414

32
g-index

42
all docs

42
docs citations

42
times ranked

1309
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 445-452.	3.3	9
2	Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues. <i>Biomolecules</i> , 2022, 12, 272.	4.0	11
3	Assessment of Neuroendocrine Changes and Hypothalamo-Pituitary Autoimmunity in Patients with COVID-19. <i>Hormone and Metabolic Research</i> , 2022, 54, 153-161.	1.5	15
4	The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. <i>Cardiovascular Diabetology</i> , 2022, 21, 42.	6.8	54
5	Change in Circulating Levels of Endothelial Progenitor Cells and Sexual Function in Women With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	1
6	European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events. <i>Pharmaceuticals</i> , 2022, 15, 677.	3.8	8
7	Female Sexual Function in Young Women With Type 1 Diabetes and Additional Autoimmune Diseases. <i>Journal of Sexual Medicine</i> , 2021, 18, 219-223.	0.6	4
8	Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2021, 31, 884-894.	4.5	25
9	Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 17.	6.8	27
10	New insights into vitamin D regulation: is there a role for alkaline phosphatase?. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1891-1896.	3.3	8
11	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. <i>Diabetes Care</i> , 2021, 44, 1353-1360.	8.6	22
12	Antibiotic resistance in diabetic foot infection: how it changed with COVID-19 pandemic in a tertiary care center. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108797.	2.8	18
13	Hypothalamic-Pituitary Autoimmunity and Related Impairment of Hormone Secretions in Chronic Fatigue Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e5147-e5155.	3.6	8
14	Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108958.	2.8	9
15	Renal and metabolic effects of SGLT-2i and DPP-4i according to basal estimated glomerular filtration rate: Analysis from GIOIA, an observational prospective study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108990.	2.8	0
16	When amputation is not the end of the challenge: A successful therapy for osteomyelitis and soft tissue infection in a patient with type 1 diabetes. <i>Journal of Diabetes Investigation</i> , 2021, , .	2.4	2
17	GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. <i>Cardiovascular Diabetology</i> , 2021, 20, 189.	6.8	104
18	Mediterranean diet in type 2 diabetes: An updated overview of pharmacological activities of cardiometabolic and reproductive outcomes. <i>Current Opinion in Pharmacology</i> , 2021, 60, 27-33.	3.5	6

#	ARTICLE	IF	CITATIONS
19	Effects of Mediterranean diet on semen parameters in healthy young adults: a randomized controlled trial. <i>Minerva Endocrinologica</i> , 2021, 45, 280-287.	1.8	8
20	GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. <i>Cardiovascular Diabetology</i> , 2021, 20, 205.	6.8	18
21	Reply to the letter to the editor by Mungmunpantipantip et al.. <i>Journal of Endocrinological Investigation</i> , 2021, , 1.	3.3	2
22	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. <i>Cardiovascular Diabetology</i> , 2021, 20, 210.	6.8	31
23	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. <i>Cardiovascular Diabetology</i> , 2021, 20, 236.	6.8	63
24	Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes. <i>Frontiers in Endocrinology</i> , 2020, 11, 574315.	3.5	28
25	Diabetic Foot Problems During the COVID-19 Pandemic in a Tertiary Care Center: The Emergency Among the Emergencies. <i>Diabetes Care</i> , 2020, 43, e123-e124.	8.6	60
26	Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. <i>Cardiovascular Diabetology</i> , 2020, 19, 115.	6.8	33
27	Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemedicine during the COVID-19 pandemic in Italy. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108440.	2.8	34
28	Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2020, 43, 1146-1156.	8.6	155
29	Glucose monitoring in diabetes: A suggested algorithm to choice the best treatment option. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108242.	2.8	3
30	Sexual dysfunctions in young women with type 1 diabetes and high glucose variability: findings from the METRO study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1823-1825.	3.3	3
31	Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108114.	2.8	29
32	<p><p>Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study</p><p>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 777-784.	2.4	4
33	Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1392.	4.1	5
34	Long-term diabetic complications as predictors of foot ulcers healing failure: A retrospective study in a tertiary-care center. <i>Diabetes Research and Clinical Practice</i> , 2020, 163, 108147.	2.8	13
35	Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak?. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108219.	2.8	45
36	Remission of Pituitary Autoimmunity Induced by Gluten-Free Diet in Patients With Celiac Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2252-2261.	3.6	7

#	ARTICLE	IF	CITATIONS
37	GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2576-2580.	4.4	104
38	Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study. <i>Diabetes Research and Clinical Practice</i> , 2019, 155, 107787.	2.8	3
39	The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019, 154, 101-115.	2.8	19
40	The role of autoimmunity in pituitary dysfunction due to traumatic brain injury. <i>Pituitary</i> , 2019, 22, 236-248.	2.9	14
41	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 45.	3.5	94
42	Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2309-2313.	4.4	32